Background Standard‐dose seasonal influenza vaccines often produce modest
immunogenic responses in adults≥ 65 years old. MF59 is intended to elicit a greater …

Aim Adjuvanted influenza vaccines can overcome the poor antibody response of
conventional non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity …

Background In the elderly, traditional influenza inactivated vaccines are often only modestly
immunogenic, owing to immunosenescence. Given that adjuvantation is a means of …

Background The absolute degree of protection from influenza vaccines in older adults has
not been studied since 2001. This study aimed to show the clinical efficacy of an MF59 …

BACKGROUND: Adding adjuvants such as MF59® to influenza vaccines can enhance the
immune response. This analysis evaluated the safety profile of MF59-adjuvanted [(+) MF59] …

Background: Influenza is responsible for a significant disease burden annually, especially in
older adults. This study reviews the relative vaccine efficacy or effectiveness (rVE) of high …

Background We aimed to compare AS03-adjuvanted inactivated trivalent influenza vaccine
(TIV) with non-adjuvanted TIV for seasonal influenza prevention in elderly people. Methods …

Background There is an urgent need for improved influenza vaccines especially for older
adults due to the presence of immunosenescence. It is therefore highly relevant to compare …

Background: The elderly are at a higher risk of morbidity and mortality associated with
influenza infection than younger adults, but get less protection from conventional …

Background: The higher effectiveness of MF59®-adjuvanted trivalent influenza vaccine
(MF59-TIV) vs. nonadjuvanted TIV in preventing influenza-related hospitalizations was …